Statement: Cohort 1 of the primary trial recorded no deaths and no cases of Anemia.
Primary_evidence: Adverse Events 1:   Total: 22/96 (22.92%)   Anemia  1/96 (1.04%)   Febrile neutropenia  4/96 (4.17%)   Heart failure  1/96 (1.04%)   Abdominal pain  1/96 (1.04%)   Dysphagia  1/96 (1.04%)   Mucositis oral  1/96 (1.04%)   Nausea  1/96 (1.04%)   Vomiting  2/96 (2.08%)   Death NOS  0/96 (0.00%)   Pain  1/96 (1.04%)   Catheter related infection  1/96 (1.04%)   Enterocolitis infectious  0/96 (0.00%) Adverse Events 2:   Total: 3/60 (5.00%)   Anemia  1/60 (1.67%)   Febrile neutropenia  1/60 (1.67%)   Heart failure  1/60 (1.67%)   Abdominal pain  0/60 (0.00%)   Dysphagia  0/60 (0.00%)   Mucositis oral  0/60 (0.00%)   Nausea  0/60 (0.00%)   Vomiting  0/60 (0.00%)   Death NOS  1/60 (1.67%)   Pain  0/60 (0.00%)   Catheter related infection  0/60 (0.00%)   Enterocolitis infectious  1/60 (1.67%)